EMA PRAC identifies risk of secondary malignancies from CAR T-cell medicines

EMA CHMP grants positive opinion of Korjuny for malignant ascites

The European Medicines Agency Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the approval of trifunctional anti-CD3 x anti-EpCAM antibody Korjuny (catumaxomab) for the intraperitoneal treatment of malignant ascites in adults with EpCAM-positive carcinomas who are not eligible for further systemic anticancer therapy.

October 25, 2024

Vol.50 No.40

Drugs & Targets

EMA CHMP issues positive opinions for Tevimbra for gastric or GEJ adenocarcinoma and ESCC

The European Medicine Agency Committee for Medicinal Products for Human Use issued positive opinions recommending an extended authorization for Tevimbra (tislelizumab) in gastric or gastroesophageal junction adenocarcinoma and esophageal squamous cell carcinoma.

October 25, 2024

Vol.50 No.40

Drugs & Targets

EMA accepts marketing application for AVT03, a proposed biosimilar to Prolia and Xgeva

EMA has accepted a Marketing Authorization Application for AVT03, a proposed biosimilar candidate to Prolia and Xgeva (denosumab).

October 18, 2024

Vol.50 No.39

Drugs & Targets

EC approves Vyloy + chemo for advanced gastric and GEJ cancers

The European Commission approved Vyloy (zolbetuximab) in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2-negative gastric or gastroesophageal junction adenocarcinoma whose tumors are claudin 18.2 positive.

September 27, 2024

Vol.50 No.36

In Brief

Tampa General, Mass General Brigham strengthen relationship through BMT, CAR T collaboration

Tampa General Hospital and Mass General Brigham announced a strengthening of their affiliation with the development of new programs and services, including a bone marrow transplant program and CAR T therapy program, at TGH.

September 20, 2024

Vol.50 No.35

Clinical

Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis shows
Subgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies

A meta-analysis of 25 studies—totaling over 5,000 participants—focused on a question that has been troubling patients, physicians, and regulators: Does treatment with CAR T-cell therapy contribute to the development of secondary cancers?

September 13, 2024

Vol.50 No.34

By McKenzie Prillaman

EMA PRAC identifies risk of secondary malignancies from CAR T-cell medicines

YOU MAY BE INTERESTED IN

EMA CHMP grants positive opinion of Korjuny for malignant ascites

EMA CHMP issues positive opinions for Tevimbra for gastric or GEJ adenocarcinoma and ESCC

EMA accepts marketing application for AVT03, a proposed biosimilar to Prolia and Xgeva

EC approves Vyloy + chemo for advanced gastric and GEJ cancers

Tampa General, Mass General Brigham strengthen relationship through BMT, CAR T collaboration

Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis shows
Subgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies

Renew today!

Subscriber content

Login

EMA PRAC identifies risk of secondary malignancies from CAR T-cell medicines

YOU MAY BE INTERESTED IN

EMA CHMP grants positive opinion of Korjuny for malignant ascites

EMA CHMP issues positive opinions for Tevimbra for gastric or GEJ adenocarcinoma and ESCC

EMA accepts marketing application for AVT03, a proposed biosimilar to Prolia and Xgeva

EC approves Vyloy + chemo for advanced gastric and GEJ cancers

Tampa General, Mass General Brigham strengthen relationship through BMT, CAR T collaboration

Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis showsSubgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies

Login

Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis shows
Subgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies